Funding & Deals
Sep 27, 2026 · 1 min read · 84,176 views
Updated: Electra says $350M IPO will help it become a commercial biotech
E
Elena Marsh
Editorial · Sep 27, 2026
Electra Therapeutics became the 21st biotech of 2026 to go through with an IPO after pricing its $350 million Nasdaq debut on Thursday evening. The Bay Area biotech will use the funds to
← Previous
Akeso details survival win for its PD-1xVEGF drug versus Keytruda
Next →
After years of hype, the first AI-designed drugs fall short in the clinic
